Release Details

Idera to Present at the 37th Annual Cowen and Company Health Care Conference

Mar 02, 2017

CAMBRIDGE, Mass. and EXTON, Pa., March 02, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera’s Chief Medical Officer, Joanna Horobin, M.B., Ch.B. will provide a corporate overview and update at the 37th Annual Cowen and Company Health Care Conference on Wednesday, March 8, 2017 at 11:20 a.m. Eastern Time at the Boston Marriott Copley Place.

Live audio webcast of Idera’s presentations will be accessible in the Investors and Media section of Idera’s website at  Archived versions will also be available on the Company’s website after the event for 90 days. 

About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit


Investor and Media Contact
Robert Doody
VP, IR & Corporate Communications
617-679-5515 (office)
484‐639‐7235 (mobile)

Primary Logo

Idera Pharmaceuticals, Inc.